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Abstract
Currently, ionizing radiation (IR) plays a key role in the agricultural and medical industry, while accidental exposure
resulting from leakage of radioactive sources or radiological terrorism is a serious concern. Exposure to IR has various
detrimental effects on normal tissues. Although an increased risk of carcinogenesis is the best-known long-term
consequence of IR, evidence has shown that other diseases, particularly diseases related to inflammation, are common
disorders among irradiated people. Autoimmune disorders are among the various types of immune diseases that have
been investigated among exposed people. Thyroid diseases and diabetes are two autoimmune diseases potentially
induced by IR. However, the precise mechanisms of IR-induced thyroid diseases and diabetes remain to be elucidated,
and several studies have shown that chronic increased levels of inflammatory cytokines after exposure play a pivotal
role. Thus, cytokines, including interleukin-1(IL-1), tumor necrosis factor (TNF-α) and interferon gamma (IFN-γ), play a
key role in chronic oxidative damage following exposure to IR. Additionally, these cytokines change the secretion of
insulin and thyroid-stimulating hormone(TSH). It is likely that the management of inflammation and oxidative damage
is one of the best strategies for the amelioration of these diseases after a radiological or nuclear disaster. In the present
study, we reviewed the evidence of radiation-induced diabetes and thyroid diseases, as well as the potential roles of
inflammatory responses. In addition, we proposed that the mitigation of inflammatory and oxidative damage markers
after exposure to IR may reduce the incidence of these diseases among individuals exposed to radiation.
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Background
Every year, millions of people are exposed to ionizing radi-
ation resulting from diagnostic or interventional radiology
and radiotherapy. In addition, nuclear and radiologic di-
sasters pose a threat to all individuals worldwide. In
addition to the killing effects of ionizing radiation at high
doses, exposure to sub-lethal doses may result in various
diseases, such as carcinogenesis, cataract, and cardiovas-
cular disease [1, 2].
Although genomic instability and carcinogenesis are the
most important concerns of ionizing radiation, studies
have revealed that exposure to IR can strongly affect im-
mune system responses, leading to changes in the normal
functions of immune responses [3]. These effects may be
responsible for various diseases among exposed people.
Studies have proposed that chronic inflammation and
continuous free radical production are responsible for sev-
eral diseases after radiotherapy or radiation accident. Sev-
eral studies have proposed that 25% to 50% of all cancers
may be related to chronic inflammation [4–6]. Moreover,
continuous free radical production, resulting from inflam-
matory responses, can disrupt organ function. For ex-
ample, chronic oxidative damage in the kidneys of
individuals with diabetes is mediated by increased insulin-
like growth factor 1(IGF-1) and nicotinamide adenine di-
nucleotide phosphate(NADPH) oxidase enzymes [7, 8].
This situation has been confirmed for other organs, such
as Crohn’s disease and ulcerative colitis in the gastrointes-
tinal system, pancreatitis, and rheumatoid arthritis [9–13].
Under normal conditions, there is a balance between
the levels of free radicals and the antioxidant defenses
that help prevent reactive intermediates from damaging
cells and tissues. Free radicals play an important role in
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cell signaling; however, excessive amounts of reactive
oxygen species(ROS), as observed following exposure to
IR, can cause damage to cellular genetic contents, pro-
teins, and lipids [14]. Free radicals have different types
in cells, including superoxide (O2•-), nitric oxide (NO),
and the hydroxyl radical (OH•). However, other types of
molecular species, such as hydrogen peroxide (H2O2) and
peroxynitrite (ONOO-), can be produced by IR interac-
tions or subsequent metabolites [15, 16].
There is a strong relationship between chronic inflam-
mation and oxidative damage after exposure to IR [17].
IR can alter the numbers and functions of immune sys-
tem cells in irradiated organs. Increased numbers of
macrophages and lymphocytes T (T-cells) induce the se-
cretion of several inflammatory mediators, such as NF-
κB and SMAD2/3, and cytokines, such as IL-1, IL-2, IL-
6, IL-8, IL-33, tumor necrosis factor (TNF-α), transform-
ing growth factor beta (TGF-β), and interferon gamma
(IFN-γ) [18]. The elevated level of these inflammatory
mediators is associated with the release of prostaglan-
dins and free radicals, including reactive oxygen species
(ROS) and nitric oxide (NO) [19]. Under conditions,
such as exposure to high doses of IR during a radiation
disaster, these inflammatory responses may continue for
years after exposure [20]. In this situation, chronic in-
flammation and its consequences may disrupt the func-
tions of irradiated organs [21].
Radiation toxicity in radiological and nuclear
disasters
Ionizing radiation is responsible for the production of
free radicals, including reactive oxygen species and re-
active nitrogen species. When bone marrow or gastro-
intestinal systems receive an acute high dose of radiation
(typically more than 4 Gy), exposed people can die as a
result of acute radiation syndrome [22]. However, studies
have shown that the exposure of other organs, such as the
lung and heart, to radiation resulting from inhaling radio-
nuclides or external exposure can cause acute reactions,
leading to the inactivation of these organs and death after
a number of months [23, 24]. In addition to the risk of
death after a radiological or nuclear disaster, many people
exposed to radiation-contaminated areas show signs of
disease in years long after exposure [25, 26].
Hundreds of radiological and nuclear events have oc-
curred since the World War II [27]. The nuclear disaster
in Hiroshima and Nagasaki during the World War II is
the most important example of the importance of radi-
ation toxicity in the development of various types of dis-
eases. In this disaster, more than 150,000 people
immediately died, while thousands of people received sub-
lethal doses [28]. Subsequently, the Chernobyl disaster
was the most important environmental nuclear disaster
[29]. Epidemiological studies performed some decades
after the nuclear disaster have confirmed chronic changes
in several biological factors, particularly the factors related
to cancer and the immune system [30]. Increased inci-
dences of thyroid diseases resulting from radioactive iod-
ine was one of the most common diseases in some
adjacent countries to Chernobyl [31]. The incidence of
cancer and increased level of inflammatory markers have
been reported among Hiroshima and Nagasaki survivors
[32]. The chronic inflammation induced by IR as a result
of changes in adaptive and innate immune responses is re-
sponsible for various disorders among exposed people.
These disorders include cardiovascular diseases, diabetes,
and damage to thyroid function [33, 34].
Innate and adaptive immune responses:
Mechanisms of autoimmunity diseases
The innate immune system provides the host with an im-
mediate response against pathogens. This system senses
pathogens and damaged cells through damage associated
molecular patterns (DAMPs) by pattern recognition re-
ceptors (PRRs). PRRs are ligands primarily expressed by
innate immune system cells, such as macrophages, T-cells,
and dendritic cells (DCs) [35]. The most important type of
PRRs is toll-like receptors (TLRs). TLRs detect a variety of
DAMPs, such as oxidized DNA, high-mobility group box 1
(HMGB1), and uric acid [36, 37]. Studies have proposed
that TLR2, TLR4, TLR5, TLR7, and TLR9 are the main
PRRs, which stimulate inflammatory responses following
the exposure of innate immune cells to pathogens or dam-
aged cells [38, 39]. These TLRs, through the stimulation
of myeloid differentiation primary response 88 (MyD88),
induce the upregulation NF-κB and other transcription
factors, leading to the secretion of pro-inflammatory cyto-
kines [40]. For example, the ligation of DAMPs to TLR7
and TLR9 can stimulate the secretion of IFN-γ from in-
flammatory cells, while TLR2 and TLR4 can upregulate
the secretion of IL-1β, IL-6, and IL-8 [41].
Another part of the immune system includes the adap-
tive immune system mediated by B and T cells. The B cells
mediate humoral immunity, while T cells mediate cellular
immunity. These cells distinguish self-antigens from for-
eign antigens. The B cell receptors (BCRs) and T cell re-
ceptors (TCRs), which are generated through VDJ
recombination, are responsible for the recognition of anti-
gens [42]. However, antigen-presenting cells (APCs), in-
cluding DCs, B-cells, and macrophages, present antigens
to these cells. The interaction of these immune cells is ne-
cessary for the detection and response of the adaptive im-
mune system. Presenting antigens by APCs is associated
with the activation of T cells, including CD8+ cytotoxic T-
cells (CTL) or CD4+T helper cells [43, 44].
Typically, autoimmune diseases result from altering
the T cell-dependent control of self-reactive T cells. Ab-
normal changes in the levels of some cytokines and
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activities of APCs can result in the abnormal activation
of CTLs. DCs play a key role in presenting danger
alarms to T cells, leading to the reaction of these cells
[45]. Studies have shown that increasing the level of
some cytokines, such as IL-1, TNF-α and IFN-γ, lead to
alterations in DCs homeostasis. These cytokines may in-
duce the differentiation of immature DCs into mature
DCs. The increased differentiation of immature DCs has
been associated with various autoimmune diseases. [46].
IL-6 is another cytokine involved in the pathogenesis of
autoimmune diseases [47, 48]. Blocking these cytokines
by their antagonists and using anti-inflammatory cyto-
kines, such as TGF-β1, can reduce the severity of auto-
immune processes [49, 50]. These results indicated that
there is a strong link between chronic inflammation after
exposure to IR and autoimmune disorders.
Radiation-induced inflammation
Inflammation is one of the most important responses of
tissues to IR, which can cause damage to various organs
for years after exposure. Inflammation is a complicated
process that appears as damage of the vasculature, migra-
tion of leukocytes into the irradiated area and the release
of various immune system mediators [51, 52]. The re-
sponses of normal tissues to IR are highly dependent on
the radiation dose. With increasing radiation dose, the in-
cidence of vascular damage, hypoxia and cell necrosis in-
creases. This effect is associated with changes in the
immune system response, leading to changes in the cyto-
kine profile. The exposure of body cells to low doses of IR
(lower than 1 Gy) can stimulate anti-inflammatory effects.
This effect results from the high incidence of apoptosis
compared to necrosis, while exposure to higher doses of
IR (more than 1 Gy) leads to necrosis, rather than apop-
tosis, causing inflammation responses [18, 53].
Although vascular damage and necrosis are respon-
sible for the initiation of inflammation, under stress con-
ditions, such as exposure to a heavy dose of IR, other
types of cell death, such as apoptosis, autophagy, and
senescence, can stimulate inflammatory responses [54].
Massive DNA damage and cell death following exposure
to high doses of IR (more than 1 Gy) lead to the release
of cellular contents, such as danger alarms or DAMPs.
The most important released DAMPs after exposure to
IR include HMGB1, uric acid, and heat-shock proteins
(HSPs). In response to IR, TLR2, TLR4, TLR5 and TLR9
play a central role in the activation of inflammation
pathways via the identification of DAMPs [54, 55].
TLRs through the upregulation of inflammatory medi-
ators, such as MAPKs, NF-κB, and COX-2, trigger the
secretion of inflammatory cytokines, including IL-1, IL-
6, IL-8, TNF, IL-33, and IFN-γ. However, these cytokines
further amplify the regulation of inflammatory mediators
in a positive feedback loop [56]. In addition to inflammatory
mediators, continuous ROS and nitric oxide production
amplify the toxic effects of radiation-induced inflammation
on normal tissues. When this response is not inhibited by
anti-inflammatory mechanisms, the inflammatory cytokines
and free radicals induced by chronic inflammation disrupt
the normal function of organs [56, 57] (Fig. 1).
Evidence of IR-induced autoimmune diseases
Epidemiological studies of the atomic-bomb survivors have
recommended that IR can functionally break self-tolerance
and induce various organ-specific autoimmune dis-
eases [30, 58]. Impaired DNA damage responses are
postulated as key mechanisms involved in some auto-
immune diseases, such as type I diabetes, rheumatoid arth-
ritis, gastritis, thyroiditis, and orchitis [59]. An in-vivo study
showed that induction of autoimmune diseases occurs fol-
lowing the irradiation of both the thymus and peripheral
lymphoid organs [60]. However, there is clear evidence that
lymphocytes from patients with autoimmune diseases, such
as systemic sclerosis and rheumatoid arthritis, exhibit higher
radiosensitivity and delayed DNA damage repair responses
compared to lymphocytes from healthy donors [61, 62].
Thus, autoimmune diseases induced by radiation may be in-
volved in carcinogenesis in years long after exposure in the
irradiated population. To the best of our knowledge, thyroid
diseases and diabetes are two important autoimmune dis-
eases linked to radiation exposure in the population.
Fig. 1 The mechanisms of IR-induced inflammation or anti-inflammatory
responses. After apoptosis, macrophages detect apoptotic bodies,
leading to the secretion of anti-inflammatory cytokines, such as
transforming growth factor beta (TGF-β). This response is observed for
low doses of ionizing radiation (IR) (less than 1 Gy), where apoptosis is
more common than necrosis. However, damage associated molecular
patterns (DAMPs) released by necrotic cells after exposure to high
doses of IR stimulate T-cells and dendritic cells (DCs) to upregulate
inflammatory mediators and the secretion of inflammatory cytokines
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Thyroid autoimmune diseases
There are several reports linking autoimmune thyroid dis-
ease to therapeutic and environmental radiation expo-
sures. Examples for this claim include Japanese atomic
bomb survivors, children exposed to radioactive iodine
from 131I therapy and nuclear weapons testing at the Nev-
ada test site, and Chernobyl disaster survivors. Several
studies have reported abnormal incidences of auto-
immune reactions in the pathogenesis of thyroid diseases
and impaired natural killer (NK) cells activity against
tumor cells [63–68]. Additionally, occupational exposures
to IR among nuclear power plant, medical and laboratory
workers are related to a higher risk of autoimmune reac-
tions [69]. A study on Hiroshima and Nagasaki atomic
bomb survivors and children exposed to radioactive iodine
from nuclear weapons testing showed a linear radiation
dose response for thyroid tumors and nodules but not for
autoimmune thyroid diseases [66, 70]. However, the in-
creased risk of autoimmune thyroid diseases may have
contributed to the elevated cancer incidence among the ir-
radiated population [70].
In addition to high doses of IR in radiation therapy or
disasters, several studies have proposed that exposure to
occupational doses of IR may be associated with thyroid
autoimmune disease. In a cross-sectional study, Völzke
et al. [66] examined the potential role of the low-dose
occupational exposures to IR (mostly lower than 1–2
mSV in a year) associated with the increased risk of thy-
roid diseases. These authors used thyroid ultrasound
and antithyroxiperoxidase antibodies to detect the inci-
dence of this disease. The results showed an unusual
thyroid pattern in ultrasound imaging, particularly for
females. Moreover, the results showed that this risk is
higher for workers of a nuclear power plant, particularly
those that have been exposed for more than 5 years [71].
Imaizumi and colleagues evaluated the risk of thyroid
diseases among atomic bomb survivors exposed in utero.
Among the 319 participants that received an equal radi-
ation dose of 25 cGy, no significant thyroid disease was
detected. However, the authors proposed that a limited
statistical power may be involved in the negative result
of this study [72]. As the radiosensitivity of the uterus is
similar to that of the child, further studies with a higher
population number are needed to investigate the poten-
tial role of IR in thyroid diseases in utero.
Potential mechanisms of IR-induced thyroid autoimmune
diseases
Studies have proposed that autoimmune thyroid disease
is related to genetic background, while exposure to
toxic agents, such as ionizing radiation, is also involved
[73, 74]. Mechanisms of autoimmune thyroid diseases
are different, which can be observed as changes in thyroid
hormone action, resulting in a change in circulating
hormones. However, thyroid malfunctions may result
from pituitary and thyrotropin secretion [75].
The most common thyroid diseases following expos-
ure to ionizing radiation are hypofunction and thyroid
nodules. However, the increased incidence of thyroid
cancers may be involved in these diseases [76]. A reduc-
tion in function of the thyroid is the most common
autoimmune disease induced by IR. Graves’ disease has
been implicated in hypothyroidism or hyperthyroidism
following exposure. In addition, a reduction of the
thyroid-stimulating hormone(TSH) receptor in patients
treated with radioiodine is associated with the increased
probability of autoimmune hyperthyroidism [77].
Several studies have proposed that inflammatory re-
sponses may be involved in autoimmune diseases. For
example, the production of inflammatory cytokines, such
as IL-1 and IL-6, in thyroid-infiltrating mononuclear and
follicular cells has been associated with Graves’ disease
[78]. Macrophages and NK cells play a central role in
the secretion of IL-1 and IL-6. IL-1 can stimulate the re-
lease of IL-6 in thyrocytes. Moreover, this effect may be
potentiated by TNF-α. The upregulation of these inflam-
matory cytokines can suppress the secretion of thyroid
hormones, such as TSH, and reduce the serum levels of
Thyroxine(T4) and Triiodothyronine (T3) [79, 80].
Diabetes
Several studies have reported a link between whole body
or abdomen irradiation and the increased risk of dia-
betes [81–83]. A previous study showed a two-fold in-
creased risk of diabetes mellitus (especially type 2) for
cancer survivors treated by radiotherapy for acute mye-
loid leukemia (AML), neuroblastoma, Wilms tumor, and
Hodgkin lymphoma. Additionally, survivors of acute
lymphoblastic leukemia (ALL) and brain tumors showed
an increased risk of obesity in adulthood. The results of
this study showed that neuroblastoma survivors have the
highest likelihood of becoming diabetic compared with
siblings. This issue is more obvious for individuals who
have been exposed to whole body irradiation and abdo-
men radiotherapy for childhood cancer [84, 85]. The as-
sociation between Hodgkin lymphoma treatment and
the increased risk of diabetes mellitus has been con-
firmed [86]. In a 30-year follow-up study of 2520 child-
hood cancer survivors, Vathaire et al. [83] showed that
irradiation to the tail of the pancreas is closely associated
with the increased risk of diabetes. This study showed
that the risk of diabetes has a strong relationship with
radiation dose. The irradiation of other parts of the pan-
creas did not show any relationship with diabetes risk
[87]. The mechanisms of IR-induced diabetes are not
fully understood. However, the impairment of specific β-
cell and insulin release among cancer survivors may be
involved [88].
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Potential mechanisms of IR-induced diabetes
In contrast to the aforementioned reports, several studies
have indicated that low-dose radiation (0.5 Gy) has a pre-
vention effect on the development of diabetes. Mechanisms
may include the induction of pancreatic antioxidants and
protection of the β cells from oxidative damage and immu-
nomodulation to preserve pancreatic function [89]. How-
ever, the precise molecular mechanism of β-cell damage
after irradiation is not known, and chronic inflamma-
tion likely plays a key role in this process. It is feasible
that pro-inflammatory cytokines, such as IL-1β and
IFN-γ, be involved in the signaling pathways that cause
pancreatic β-cell death and dysfunction [90]. Moreover,
activation of the NLRP3 inflammasome may stimulate
oxidative damage through hyperglycemia [91–93].
However, there is some evidence that the proposed
genotype is involved in the risk of radiation-induced
diabetes. A study of atomic-bomb survivors showed a
relationship between human leukocyte antigen (HLA)
genotypes and diabetes. Survivors with the DQA1*03-
DRB1*09 or DQA1*0401-DRB1*08 haplotypes showed
an increased risk of diabetes with radiation dose [94].
Gastritis
Autoimmune gastritis is a chronic inflammatory gastric
condition characterized by the increased number and ac-
tivity of inflammatory cells, such as lymphocytes. Chronic
gastritis results from the destruction of the mucosa, lead-
ing to pain, atrophy, inflammation and bleeding [95]. This
type of autoimmune disease is common for clinical tumor
treatment in which the stomach is within the field of
radiotherapy. Gastritis typically appears after the gastric
exposure to doses higher than 40–50 Gy [96]. Although
the molecular mechanisms of gastritis following exposure
to radiation have not been completely determined, several
studies have reported that the suppression of inflamma-
tion using anti-inflammatory drugs can help control this
condition [97–99]. Graziani et al. proposed that radiation-
induced gastritis in patients with pancreatic cancer can be
stimulated by other drugs, such as erlotinib, which is an
antagonist for the expression of epidermal growth factor
receptor [100] (Fig. 2).
Potential role of radiation mitigators to prevent
radiation-induced inflammation diseases
Although the administration of antioxidants or other ra-
diation modifiers prior to exposure has the highest effi-
ciency, several studies have proposed that chronic
treatment with antioxidant agents may reduce the long-
term consequences of radiation. For example, the treat-
ment of Chernobyl survivors with antioxidants, such as
beta-carotene, reduced the serum level of oxidative dam-
age markers [101]. As previously described, several stud-
ies have confirmed that chronic inflammation plays a
key role in the detrimental effects of radiation, including
continuous oxidative stress and even carcinogenesis.
Treatment with some antioxidants, such as ascorbic
acid, selenium, and other antioxidant mixtures, have
exhibited the ability to ameliorate increased oxidative
damage and the levels of inflammatory cytokines, such
as IL-1, IL-6, TNF-α, IFN-γ, and TGF-β [102–104]. In
vivo studies have confirmed the mitigatory effects of
Fig. 2 Model for radiation-induced inflammatory autoimmune diseases. In this model, ionizing radiation (IR) induces reactive oxygen species
(ROS) production and necrosis, leading to the activation of inflammatory transcription factors and secretion of inflammatory cytokines. This effect
is associated with further ROS production and cell death. The activation of the inflammasome in diabetic patients is involved in hyperglycemia,
leading to oxidative damage. Moreover, inflammatory cytokines can stimulate the differentiation of dendritic cells (DCs), which present further
necrosis antigens to T-cells
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certain antioxidants and immunomodulators for other
radiation-induced inflammation diseases, such as nephro-
toxicity, pneumonitis and fibrosis [105–109]. As auto-
immune diseases have a direct relation to these factors, it
is likely that the amelioration of chronic inflammation
may help reduce the incidence of various radiation-
induced diseases, including autoimmune diseases.
Conclusions
Although there is a long way to illustrate the complete
mechanisms of IR-induced diabetes and thyroid diseases,
recent studies suggest that the chronic upregulation of
inflammatory mediators and cytokines play a key role. It
is feasible that long-term exposure to a high level of
some cytokines, particularly IL-1β and IFN-γ, can dis-
rupt the normal function of thyrocytes in the thyroid, as
well as beta cells in the pancreas. However, it is likely
that genetic background plays a key role in the appear-
ance of autoimmune diseases. Although there is no sug-
gested strategy for the prevention or reduction of
autoimmune diseases following exposure to IR during
radiotherapy or radiation accidents, there may be several
solutions, such as the administration of radioprotectors,
anti-inflammatory agents, or radiation mitigators. How-
ever, to date, there is no evidence to confirm this idea.
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